DUAC: HELPING PATIENTS WITH ACNE FOR OVER 15 YEARS
When it comes to choosing a first-line treatment for patients with mild to moderate acne, you need something they can rely on.
Duac has been helping patients with mild to moderate acne for over 15 years
- Duac is a fixed-dose combination that brings together clindamycin and benzoyl peroxide, in a simple and convenient once-daily gel 1
- Duac has demonstrated efficacy and tolerability in clinical studies vs. monotherapy and other comparable fixed-dose combinations 3-6 and is supported by 15 years of pharmacovigilance data 12
Delivering visible improvements for patients
- Duac provides comparable improvements in inflammatory and noninflammatory lesions to adapalene/BPO at week 12, with a faster time to treatment success* and favourable tolerability 4
- A higher number of patients were satisfied† with Duac than with adapalene/BPO and fewer patients miss applications due to tolerability issues or adverse events during the first few weeks of treatment 47
Duac is a recommended fixed-dose combination
- Duac: the European Dermatology Forum (EDF) acne treatment guidelines give a high strength recommendation for fixed-dose combinations of benzoyl peroxide (BPO) + clindamycin (such as Duac) or BPO + adapalene as therapy for the treatment of mild to moderate papulopustular acne 8
- The strength of recommendation considered all aspects of the treatment decision, such as efficacy, safety profile, patient preference, and the reliability of the existing body of evidence 8
* Defined as an improvement of 2 grades or more from baseline on the investigator’s static global scale assessment (ISGA) scale (a 6-point scale [0=clear skin with no inflammatory lesions; 5=severe acne with many inflammatory and non-inflammatory lesions and more than a few nodular lesions]) 4
† In two eight-week studies, with a randomized, single-blind, 2-week split-face phase, a higher number of patients were more satisfied with Duac than adapalene/BPO during the first (65.3% vs. 31.9%) and second week of treatment (56.2% vs. 42.5%, no p value has been provided). Both treatments were rated equally effective at reducing acne break outs. Tolerability was significantly better with Duac than adapalene/BPO as reported by investigators and patients (p<0.05).
- Duac Once Daily 5% Gel, Summary of Product Characteristics
- US FDA website. Drug Approval Packages: Duac. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/050741_duac.cfm (Accessed February 2020).
- Lookingbill DP et al. J Am Acad Dermatol 1997;37:590–595.
- Zouboulis C et al. Cutis 2009;84:223–229.
- Langner A et al. JEADV 2007;21:311–319.
- Langner A et al. Br J Dermatol 2008;158:122–129.
- Green L et al. J Clin Aesthet Dermatol 2012;5:16–24.
- Nast A et al. European Dermatology Forum. S3-Guideline for the treatment of acne (Update 2016). Available at: https://www.edf.one/dam/jcr:1f4787ea-8a52-4ec5-8c4d-5ae7bbd1201a/Document_S1_EU_Acne_Guideline_long_EDF_1.pdf (Accessed February 2020).